SEC Form 4 · accession 0001144204-15-069759
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip Macneill
Officer — VP, CFO, Treasurer, Secretary
Period of report
Dec 3, 2015
Accepted (ET)
Dec 7, 2015 · 8:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1,F2 | Dec 3, 2015 | A | 25,000 | $0.00 | A | 50,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $1.66 | Dec 3, 2015 | A | 70,625 | A | — | Dec 3, 2025 | Common Stock | 70,625 | 70,625 | D |
Explanation of responses
- F1Represents a grant of shares of restricted stock with 50% of the shares vesting on December 3, 2016 and the remaining 50% vesting on December 3, 2017. These vesting dates may be accelerated pursuant to the terms of the relevant Restricted Stock Agreement if certain circumstances occur.
- F2On December 3, 2015, the date of grant, the closing price of the Issuer's common stock on the NYSE MKT was $1.66 per share.
- F3The options vest over a 3 year period with 25% vesting on the grant date and an additional 25% vesting on each of the first, second and third anniversaries of the grant date.